{
  "schemaVersion": 1,
  "id": "research-332",
  "slug": "332-what-binding-protein-measurements-tell-us-about-semaglutide",
  "title": "What binding-protein measurements tell us about semaglutide",
  "catalogLabel": "SEMA / IGF-1 LR3",
  "productCollection": "https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3",
  "productHandles": [
    "sema-igf-1-lr3-708",
    "sema-igf-1-lr3-709"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/sema-igf-1-lr3-708",
    "https://heritagebiolabs.com/product/sema-igf-1-lr3-709"
  ],
  "readingFocus": "Methods & identity",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 257,
  "sourceYears": [
    1992,
    2025
  ],
  "paragraphs": [
    "Short amino-acid chains connected by peptide bonds are peptides. They can signal through receptors or interact with other proteins. Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment. It helps explain the difference between measuring a change in the body’s growth-factor system and administering a growth-factor analog. [1, 2]",
    "The investigators followed 34 people with type 2 diabetes who were already receiving metformin. Some received semaglutide and some received sitagliptin. The study also included a matched comparison group. Researchers measured several binding proteins over a year. They reported an increase in IGFBP-1 during treatment with either drug. The measured level of another related protein, IGFBP-rp1, did not change significantly with either treatment. These measurements concern proteins already circulating in the participants. [1]",
    "Binding proteins can affect how much IGF-1 is available to receptors. Older cell research describes IGF-1 LR3 as having lower affinity for IGF-binding proteins than ordinary IGF-1. These two observations answer separate questions. One concerns changes in the concentration of proteins in the blood during semaglutide treatment. The other concerns how a modified growth-factor molecule interacts with such proteins in laboratory research. [1, 2]",
    "The one-year study did not administer IGF-1 LR3 or measure the outcome of using it with semaglutide. It therefore cannot tell us whether that combination would change growth-factor signaling, body composition or adverse events. The available study is evidence about blood measurements during treatment with the medications it actually examined. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "E. Dániel et al. Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes. International Journal of Molecular Sciences (publication 2025-10-26).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41226444/"
    },
    {
      "number": 2,
      "citation": "R. W. Grimes and J. M. Hammond. Insulin and insulin-like growth factors (IGFs) stimulate production of IGF-binding proteins by ovarian granulosa cells. Endocrinology (publication 1992-08).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/1379161/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/332-what-binding-protein-measurements-tell-us-about-semaglutide",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/332-what-binding-protein-measurements-tell-us-about-semaglutide.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/332-what-binding-protein-measurements-tell-us-about-semaglutide.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 067 - SEMA IGF-1 LR3 and Semax.docx",
    "sourceArticleNumber": 332,
    "contentSha256": "8dfa403a1742b518cfc48c3731dcbcc082aa0712b93d6739b3a28fb5d966c5fa",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
